CERO - CERo Therapeutics Holdings Inc. Short-Term Debt to Capital

The price visualization on GURU.Markets for CERo Therapeutics (CERO), which assists in the basic asset valuation, demonstrates a metric at 0.00. The business relies on scientific achievements and test results, remaining independent of market cycles. The brand develops cutting-edge immuno-oncology methods to eliminate hidden genetic mutations. Furthermore, its US localization and the humanitarian status of its developments provide full protection against geopolitical shocks.

For CERo Therapeutics (CERO), which is adapting its post-IPO structure for the launch of clinical trials, the ratio of short-term borrowed capital to equity reflects the dependence of operational liquidity on its own reserves. This metric compares liabilities due within one year to equity, allowing investors to assess the risk of funding shortages and the efficiency of debt load management by analyzing the trends on this chart.